Chemist + Druggist is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. Please do not redistribute without permission.

Printed By


signatureRx handles thousands of prescriptions a month

Private electronic prescription company signatureRx has said it manages thousands of prescriptions per month.

signatureRx expects the number of private prescriptions it oversees to rise this year as more prescribers use the service, the company said in a statement last week (April 12).

Pharmacists can access the prescriptions via the signatureRx website, for free and without registration, using the patient’s prescription ID and date of birth in a similar method to the one used by the NHS electronic prescription service, the company said.

Patients receive the digital prescription ID from their private prescriber, which they can then take to a pharmacy of their choice, signatureRx continued.

The cost of signatureRx, which is between £1.10 and £2 per prescription, is paid by the private prescriber, the company said.

Founder Reece Samani said the system “can be used by any private clinician and any pharmacy in the country”.

For more information, visit 

Does your pharmacy receive many private electronic prescriptions?

Related Content


Pharmacy Dispenser/ Technician
Bethnal Green North, London
Salary: Up to £30,000

Apply Now



Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts